Education

B.S. in Biology, Grand Valley State University, 2005

Current Position

Research Technician, Van Andel Research Institute, Michigan, USA

Publications

1. Linklater, E. S., Tovar, E. A., Essenburg, C. J., Turner, L., Madaj, Z., Winn, M. E., Melnik, M. K., Korkaya, H., Maroun, C. R., Christensen, J. G., Steensma, M. R., Boerner, J. L. and Graveel, C. R. (2016). Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers. Oncotarget. [Epub ahead of print]
2. Sameni, M., Tovar, E. A., Essenburg, C. J., Chalasani, A., Linklater, E. S., Borgman, A., Cherba, D. M., Anbalagan, A., Winn, M. E., Graveel, C. R. and Sloane, B. F. (2016). Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models. Clin Cancer Res 22(4): 923-934.
3. Xie, Q., Su, Y., Dykema, K., Johnson, J., Koeman, J., De Giorgi, V., Huang, A., Schlegel, R., Essenburg, C., Kang, L., Iwaya, K., Seki, S., Khoo, S. K., Zhang, B., Buonaguro, F., Marincola, F. M., Furge, K., Vande Woude, G. F. and Shinomiya, N. (2013). Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy. Genes Cancer 4(7-8): 247-260.
4. Zhang, Y. W., Staal, B., Essenburg, C., Lewis, S., Kaufman, D. and Vande Woude, G. F. (2013). Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR. Mol Cancer Ther 12(8): 1429-1441.
5. Xie, Q., Bradley, R., Kang, L., Koeman, J., Ascierto, M. L., Worschech, A., De Giorgi, V., Wang, E., Kefene, L., Su, Y., Essenburg, C., Kaufman, D. W., DeKoning, T., Enter, M. A., O'Rourke, T. J., Marincola, F. M. and Vande Woude, G. F. (2012). Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A 109(2): 570-575.
6. Zhang, Y. W., Staal, B., Essenburg, C., Su, Y., Kang, L., West, R., Kaufman, D., Dekoning, T., Eagleson, B., Buchanan, S. G. and Vande Woude, G. F. (2010). MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res 70(17): 6880-6890.